Glenmark Q3 FY26: Revenue up 15% YoY, PAT at Rs 4,032 Mn

Revenue Growth 20pctEbitda Margin ExpansionResults View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹2026.10

prior close

₹1935.10

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.1%-4.0% vs market

Pharmaceuticals peers, median of 155sector-0.5%-4.6% vs sector

On the reaction day the stock moved 4.0 pts less than Nifty Midcap 150 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.1

15m

-0.3

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1-1.1-4.0-0.5-4.6

Next day

-3.4+1.8-5.1+1.4-4.8

-3.6+2.4-5.9+1.6-5.2

-2.8+2.1-4.8+0.9-3.7

-4.9+2.0-6.9+0.4-5.3

-2.4+3.6-6.0+2.4-4.8

-0.5+4.1-4.6+2.5-3.0

15d

+0.3+1.8-1.5+0.5-0.2

+5.3-0.1+5.4-1.9+7.2

+2.9-7.8+10.7-6.5+9.3

+17.9+3.1+14.8+3.1+14.8

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 consolidated revenue grew 15.1% YoY to Rs 39,006 Mn. India formulations rose 22.1% to Rs 12,986 Mn, North America up 24.2% to Rs 9,706 Mn (includes ISB 2001 out-licensing), Europe up 9.1%, Emerging Markets up 8.4%. EBITDA jumped 44.9% to Rs 8,697 Mn with margin at 22.3%. PAT grew 15.9% to Rs 4,032 Mn. 9M FY26 revenue rose 31.3% to Rs 132,119 Mn. Management highlighted RYALTRIS expansion, AbbVie deal for ISB 2001, and oncology pipeline progress.

Likely market impact

Strong topline growth and margin expansion signal improving momentum. Innovation pipeline including AbbVie-partnered ISB 2001 adds long-term optionality.